D-Wave Quantum: A 94.31% Lung-Cancer Simulation, a 15-Second Solver and a $27 Price Target All Converge on November 10
Published on 11/09/2026 at 05:10 | Editorial boerse-global.de
D-Wave Quantum has packed a dense run of announcements into the past two weeks, and the market has noticed. Shares jumped 19% on Friday, with media reports attributing the move to a broader rally across quantum-computing names after IonQ posted quarterly results and raised its revenue guidance.
The sector tailwind is only part of the story. D-Wave's own disclosures — a preliminary medical study, a faster solver, a training curriculum and a Korean partnership — give investors concrete material to weigh ahead of the company's next scheduled financial update.
A Lung-Cancer Study With a Provisional Label
On November 2, D-Wave presented preliminary results from a study on lung-cancer prediction. According to the company, researchers at Florida Atlantic University achieved 94.31% accuracy in simulation and 91.90% on D-Wave's quantum hardware using an expanded dataset. The work examined how quantum computing can be applied to lung-cancer prediction when data is limited. D-Wave explicitly stressed the provisional nature of the findings and the use of an expanded dataset.
Fifteen Seconds Versus 120
Two days earlier, on Wednesday, the company announced performance improvements to its hybrid Stride solver. In benchmark tests, the upgraded version delivered better solutions within 15 seconds than the previous version managed in 120 seconds, according to D-Wave. Alongside the solver update, D-Wave launched a three-course training path called Applied Quantum Optimization, aimed at developers and designed to speed up the practical use of quantum optimization.
Should investors sell immediately? Or is it worth buying D-Wave Quantum?
That comparison is the most tangible yardstick for judging technical progress: D-Wave is measuring the new software against its own predecessor, making its own development the benchmark. The finding favors the company provided the advantage holds up on the tasks customers actually want to run. How much a faster result matters depends on whether it is practically usable — which is why the company's wording counts. D-Wave speaks of better solutions in the benchmark test, a claim that ties outcome quality to time spent. For investors, that is a more meaningful test than an isolated speed figure. The accompanying learning path fits the same logic: more capable tools and their application belong together, and the educational component gains weight if it helps users actually exploit the optimization capabilities.
Korea, and a Valuation Reset
Roughly two weeks ago, D-Wave and LG CNS signed a non-binding memorandum of understanding. The two companies intend to push the adoption of quantum optimization in South Korea and international markets, combining D-Wave's annealing technology with LG CNS's optimization and systems-integration capabilities.
Sentiment on valuation has moved in the opposite direction. On November 2, Craig Ellis of B. Riley Securities cut his price target to $27 from $40 while keeping a Buy rating — confidence and a reduced valuation yardstick side by side. Product progress therefore carries weight only if D-Wave can turn it into economic benefit; the industry upswing provides the tailwind, but execution must support the longer-term valuation.
The November 10 Test
The next scheduled financial event is the release of third-quarter 2026 results on November 10, before the market opens, followed by a webcast on results and outlook at 8:00 a.m. US Eastern time. For investors, that sets up a clear question: what economic development stands behind the technical progress? That link is where D-Wave will be measured — with the improved solver as the concrete argument, whose reach will be decided in application.
Ad
D-Wave Quantum Stock: New Analysis - 9 November
Fresh D-Wave Quantum information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
